Survey: Lived experience & Quality of life
Call for participants – “Exploring the lived experiences and quality of life of individuals affected by CAH”
If you’re 18 years and over and living with CAH, tell us how CAH affects your life in an individual discussion held at a convenient time face-to-face or online.
The aim of this study is to find out how CAH affects the quality of life of people affected by this condition. We will be carrying out interviews with people affected by CAH to find out how having this condition affects people’s daily lives and well-being at different stages in their life. The study findings will be used to help us develop a quality of life questionnaire that focuses on the unique issues affecting people with CAH. The questionnaire could eventually be used by health professionals and researchers to improve the care of individuals with the condition.
Individuals over the age of 18 with a diagnosis of CAH are eligible to take part in this study. Partners or relatives of people with CAH are also welcome to participate. The study will involve a one-to-one online or face-to-face interview at a convenient date and time. We expect the interviews to last about an hour. A £20 Amazon voucher will be provided to people who take part as reimbursement for their time.
The research is being led by Professor Aled Rees, Professor of Endocrinology and Consultant Endocrinologist Cardiff University, in collaboration with Cardiff Metropolitan University and Living with CAH. The study has been approved by the Cardiff University School of Medicine Research Ethics Committee: 24/32.
If you are interested in taking part in the study, download the flier here.
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
New NICE Guidelines – identification and management of adrenal insufficiency
The publication of new NICE (National Institute for Health and Care Excellence) guidelines - "Adrenal insufficiency: identification and management" marks a significant advancement in the management and treatment of primary, secondary and tertiary adrenal...
Survey: Paediatric Adrenal Insufficiency Education
This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...
Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It is an oral, selective ACTH antagonist. Atumelnant is now in Phase 2 of development and you can read the latest...